Currently, the evaluation and treatment of chronic inflammatory diseases relies on specific clinical signs accompanied with single or multiple marker(s) for that disease. Despite that, these diseases share a common innate immune mechanism involved upregulation of “Inflammasome” that have been proved in its implication in the pathologic mechanism (s) and direct irreversible conversion of pro-interleukin 1β and pro-interleukin 18 into active IL-1b and active IL-18 contributing in disease progression and tissue damage, suggesting a common theranostic target to reduce inflammatory mechanism.
(FULL ARTICLE LINK) Read more ...
1/1/2018
|
|
|